Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025
Ligand (Nasdaq: LGND) will report third quarter 2025 financial results on Thursday, November 6, 2025. A conference call will begin at 8:30 AM Eastern Time to discuss results and provide a business update.
Investors can join by phone in the U.S. and Canada at (800) 715-9871 or internationally at (646) 307-1963 using Conference ID 3661098. A live webcast and replay will be available via the company webcast link.
Ligand (Nasdaq: LGND) riferirà i risultati finanziari del terzo trimestre 2025 giovedì 6 novembre 2025. Una conference call inizierà alle 8:30 AM Eastern Time per discutere i risultati e fornire un aggiornamento sull'attività.
Gli investitori possono partecipare telefonicamente negli Stati Uniti e in Canada al (800) 715-9871 o a livello internazionale al (646) 307-1963 usando l'ID conferenza 3661098. Una trasmissione in diretta e una replica saranno disponibili tramite il link al webcast aziendale.
Ligand (Nasdaq: LGND) reportará los resultados financieros del tercer trimestre de 2025 el jueves 6 de noviembre de 2025. Una conferencia telefónica dará inicio a las 8:30 AM Eastern Time para discutir los resultados y proporcionar una actualización comercial.
Los inversionistas pueden unirse por teléfono en EE. UU. y Canadá al (800) 715-9871 o internacionalmente al (646) 307-1963 usando el Conference ID 3661098. Una transmisión en vivo y la repetición estarán disponibles a través del enlace de webcast de la empresa.
Ligand (Nasdaq: LGND) 는 2025년 3분기 재무 실적을 2025년 11월 6일 목요일에 발표합니다. 발표는 동부 표준시 8:30 AM에 시작되어 실적 및 기업 업데이트를 논의합니다.
투자자들은 미국 및 캐나다에서 전화로 (800) 715-9871 또는 국제적으로 (646) 307-1963으로 Conference ID 3661098를 사용하여 참여할 수 있습니다. 라이브 웹캐스트 및 재방송은 회사의 웹캐스트 링크를 통해 제공됩니다.
Ligand (Nasdaq : LGND) annoncera les résultats financiers du troisième trimestre 2025 le jeudi 6 novembre 2025. Une conférence téléphonique débutera à 8:30 AM Eastern Time pour discuter des résultats et fournir une mise à jour sur l'activité.
Les investisseurs peuvent se joindre par téléphone aux États-Unis et au Canada au (800) 715-9871 ou internationalement au (646) 307-1963 en utilisant l'identifiant de conférence 3661098. Une diffusion en direct et une réécoute seront disponibles via le lien webcast de l'entreprise.
Ligand (Nasdaq: LGND) wird die Geschäftsergebnisse des dritten Quartals 2025 am Donnerstag, 6. November 2025 melden. Ein Conference Call beginnt um 8:30 AM Eastern Time, um die Ergebnisse zu besprechen und ein Update zum Geschäft zu geben.
Investoren können sich telefonisch in den USA und Kanada unter (800) 715-9871 oder international unter (646) 307-1963 mit der Conference ID 3661098 verbinden. Ein Live-Webcast und eine Wiederholung werden über den Unternehmens-Webcast-Link verfügbar sein.
Ligand (Nasdaq: LGND) سيعلن عن نتائج مالية للربع الثالث من عام 2025 في يوم الخميس 6 نوفمبر 2025. ستبدأ مكالمة المؤتمر في 8:30 صباحًا بتوقيت الساحل الشرقي لمناقشة النتائج وتقديم تحديث للأعمال.
يمكن للمستثمرين الانضمام عبر الهاتف في الولايات المتحدة وكندا على الرقم (800) 715-9871 أو دوليًا على الرقم (646) 307-1963 باستخدام معرف المؤتمر 3661098. سيكون هناك بث مباشر وإعادة عرض متاحان عبر رابط webcast للشركة.
- None.
- None.
JUPITER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update.
Conference Call and Webcast Information
| Date: | Thursday, November 6, 2025 |
| Time: | 8:30 AM Eastern Time |
| Conference Call: | (800) 715-9871 (U.S. & Canada) (646) 307-1963 (International) Conference ID 3661098 |
| Webcast: | Live and replay webcasts of the call are available here. |
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X and LinkedIn.
We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.
Contacts
Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761
Media:
Kellie Walsh
media@ligand.com
(914) 315-6072
FAQ
When will Ligand (LGND) report third quarter 2025 results?
What time is the Ligand (LGND) Q3 2025 earnings call?
How can I join the Ligand (LGND) November 6, 2025 conference call?
Will Ligand (LGND) provide a webcast of the Q3 2025 call?
Where can investors find the replay of Ligand (LGND) Q3 2025 webcast?
What will Ligand (LGND) discuss on the November 6, 2025 call?
